Clinical Trials Arena5d agoneutral
FDA approval of mFLUSIVA highlights Moderna’s position in mRNA marketmFLUSIVA is now the first and only mRNA standalone seasonal influenza vaccine on the market, marking a major advancement for the field.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
54last 24h
1814last 7d
298● bullish (7d)
171● bearish (7d)
205publishers
Barchart9d agoneutral
MRNA Stock Gets a Shot in the Arm as FDA Approves Moderna Flu VaccineModerna has secured FDA approval for its flu vaccine mFLUSIVA. But does that warrant buying MRNA shares today? Let’s find out!
InvestorsHub9d agoneutral
Moderna secures FDA approval for its first mRNA influenza vaccineModerna (NASDAQ:MRNA) announced on Thursday that the U. S.
The Wall Street Journal9d agoneutral
FDA Approves First mRNA Flu Vaccine in Win for Moderna After Arduous ReviewThe Food and Drug Administration approved Moderna’s mRNA-based flu vaccine for adults ages 50 and older, clearing the first shot of its kind after a review process that nearly collapsed in February. The vaccine, called mFlusiva, uses the same mRNA technology as Moderna’s Covid-19 shots. It could reach pharmacies in time for the coming flu season, which typically starts in the fall.